Medical care expenditures for selected circulatory diseases: Opportunities for reducing national health expenditures

Medical Care

Volumn 37, Issue 10, 1999, Pages 994-1012

  Hodgson, Thomas A ^a   Cohen, Alan J ^b  

^a NATIONAL CENTER FOR HEALTH STATISTICS   (United States)

^b NONE

Author keywords

Circulatory diseases; Costs; Expenditures

Indexed keywords

AGE DISTRIBUTION; AGED; CARDIOVASCULAR DISEASE; CLASSIFICATION; ECONOMICS; FEE; FEMALE; GOVERNMENT; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH SERVICE; HOME CARE; HOSPITALIZATION; HUMAN; MALE; MIDDLE AGED; REVIEW; SEX RATIO; STATISTICS; UNITED STATES;

AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; FEMALE; HEALTH EXPENDITURES; HOME CARE SERVICES; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; NATIONAL CENTER FOR HEALTH STATISTICS (U.S.); PERSONAL HEALTH SERVICES; PRESCRIPTION FEES; SEX DISTRIBUTION; UNITED STATES; UNITED STATES CENTERS FOR MEDICARE AND MEDICAID SERVICES;

EID: 0033209685     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005650-199910000-00004     Document Type: Article

References (67)

1. Adams PF, Marano MA. Current estimates from the National Health Interview Survey, 1994. National Center for Health Statistics. Series 10, issue 193. Vital Health Stat 1995:82-104.
2. Collins JG. Prevalence of selected chronic conditions: United States, 1990-92. National Center for Health Statistics. Series 10, issue 194. Vital Health Stat 1997:22-28.
3. Graves EJ, Gillum BS. Detailed diagnoses and procedures, National Hospital Discharge Survey, 1995. National Center for Health Statistics. Series 13, issue 130. Vital Health Stat 1997:4-31.
4. Schappert SM. Ambulatory care visits to physician offices, hospital outpatient departments, and emergency departments: United States, 1995. National Center for Health Statistics. Series 13, issue 129. Vital Health Stat 1997:19-22.
5. Anderson RN, Kochanek KD, Murphy SL. Report of final mortality statistics, 1995. National Center for Health Statistics Monthly Vital Stat Report 1997;45(11):1-79.
6. Ginsberg PB, Pickreign JD. Tracking health care costs. Health Affairs 1996;15(3):140-149.
7. Levit KR, Lazenby HC, Braden BR, et al. National health expenditures, 1996. Health Care Financ Rev 1997;19(1):161-200.
8. Rice DP. Estimating the cost of illness. Health Economics Series Number 6. Washington: Public Health Service, 1966.
9. Public Health Service and Health Care Financing Administration. International Classification of Diseases, 9th Revision, clinical modification. Washington: Public Health Service, 1980.
10. Cooper BS, Rice DP. The economic cost of illness revisited. Soc Secur Bull 1976;39(2):21-36.
11. Berk A, Paringer L, Mushkin SJ. The economic cost of illness fiscal 1975. Med Care 1978;16:785-790.
12. Hodgson TA, Kopstein AN. Health care expenditures for major diseases in 1980. Health Care Financ Rev 1984;5(4):1-12.
13. Rice DP, Hodgson TA, Kopstein AN. The economic costs of illness: A replication and update. Health Care Financ Rev 1985;7(1):61-80.
14. Byerly E, Deardorff K. National and state population estimates: 1990 to 1994. Current Population Reports. Series P-25, no. 1127:1-70. US Washington: Department of Commerce, July 1995.
15. Mitchell JB, Bubolz T, Paul JE, et al. Using Medicare claims for outcomes research. Med Care 1994;32:JS38-JS51.
16. National Center for Health Statistics. Health, United States, 1996-97 and Injury Chartbook. Hyattsville, Md: National Center for Health Statistics, 1997.
17. Edwards W, Berlin M. Questionnaires and data collection methods for the Household Survey and the Survey of American Indians and Alaska Natives. National Medical Expenditure Survey Methods 2. Rockville, Md: National Center for Health Services Research and Health Care Technology Assessment, 1989.
18. IMS America. Information Services Manual. Plymouth Meeting, Pennsylvania, 1994.
19. Schappert SM. Ambulatory care visits to physician offices, hospital outpatient departments, and emergency departments: United States, 1995. National Center for Health Statistics. Series 13, issue 129. Vital Health Stat 1997:19-22.
20. Gardocki GJ, McLemore T, DeLozier JE. The National Ambulatory Medical Care Complement Survey: United States, 1980. National Center for Health Statistics. Series 13, issue 77. Vital Health Stat 1984:5-7.
21. Miller ME, Zuckerman S, Gates M. How do Medicare physician fees compare with private payers? Health Care Financ Rev 1993;14(3):25-39.
22. Benson V, Marano MA. Current estimates from the National Health Interview Survey, 1995. National Center for Health Statistics. Series 10, issue 199. Vital Health Stat 1998:77-78.
23. National Heart, Lung, and Blood Institute. Morbidity and Mortality: 1996 Chartbook on Cardiovascular, Lung, and Blood Diseases. Bethesda, MD: National Institute of Health, 1996.
24. Thom TJ. Economic costs of neoplasms, arteriosclerosis, and diabetes in the United States. In Vivo 1996;10:255-259.
25. Lazenby HC, Levit KR, Waldo DR, Adler GS, Letsch SW, Cowan CA. National health accounts: lessons from the U.S. experience. Health Care Financ Rev 1992;13(4):89-103.
26. Lindsey PA, Newhouse JP. Summary of a conference on national health expenditures accounting. Health Care Financ Rev 1986;7(4):87-96.
27. Haber SG, Newhouse JP. Recent revisions to and recommendations for national health expenditures accounting. Health Care Financ Rev 1991;13(1):111-116.
28. Health Care Financing Administration. Revisions to the national health accounts and methodology. Health Care Financ Rev 1990;11(4):42-54.
29. Stevens J, Cai J, Pamuk ER, Williamson DF, Thun MJ, Wood JL. The effect of age on the association between body mass index and mortality. N Engl J Med 1998;338:1-7.
30. Manson JE, Willett WC, Stampfer MJ, et al. Body weight and mortality among women. N Engl J Med 1995;333:677-685.
31. Huang Z, Willett WC, Manson JE, et al. Body weight change, and risk for hypertension in women. Ann Intern Med 1998;128(2):81-88.
32. Jeppensen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease-an eight year follow-up in the Copenhagen male study. Circulation 1998;97:1029-1036.
33. 6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA 1998;279:359-364.
34. Malinow MR, Duell PB, Hess DL, et al. Reduction of plasma homocysteine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. N Engl J Med 1998;338:1009-1015.
35. Mittleman MA, Maclure M, Sherwood JB, et al. Triggering of acute myocardial infarction onset by episodes of anger. Circulation 1995;92:1720-1725.
36. Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial infarction. JAMA 1993;270:1819-1825.
37. Frasure-Smith N, Lesperance F, Talajic M. Depression and 18-month prognosis after myocardial infarction. Circulation 1998;91:999-1005.
38. Krumholz HM, Butler J, Miller J, et al. Prognostic importance of emotional support for elderly patients hospitalized with heart failure. Circulation 1998;97:958-964.
39. Whelton PK, Appel LJ, Espeland MA, et al. Sodium reduction and weight loss in the treatment of hypertension in older persons. JAMA 1998;279:839-846.
40. Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med 1997;336:1117-1124.
41. Gillman MW, Cupples LA, Gagnon D, et al. Protective effect of fruits and vegetables on development of stroke in men. JAMA 1995;273:1113-1117.
42. Vegetables and fruit lower stroke risk. Harvard Heart Letter 1995;6(1):6-7.
43. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian simvastatin survival study (4S). Lancet 1994;344:1383-1389.
44. Stefanick ML, Mackey S, Sheehan M, Ellsworth N, Haskell WL, Wood PD. N Engl J Med 1998;339:12-20.
45. Kokkinos PF, Narayan P, Colleran JA, et al. N Engl J Med 1995;333:1462-1467.
46. Gale CR, Martyn CN, Winter PD, Cooper C. Vitamin C and risk of death from stroke and coronary heart disease in cohort of elderly people. BMJ 1995;310:1563-1566.
47. Khaw K, Woodhouse P. Interrelation of vitamin C, infection, haemostatic factors, and cardiovascular disease. BMJ 1995;310:1559-1563.
48. Robinson K, Mayer EL, Miller DP, et al. Hyperhomocysteinemia and low pyridoxal phosphatecommon and independent reversible risk factors for coronary artery disease. Circulation 1995;92:2825-2830.
49. Roose SP, Laghrissi-Thode F, Kennedy JS, et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA 1998;279:287-291.
50. Emotions and heart disease. Harvard Heart Letter 1998;8(11):3-4.
51. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin men and women with average cholesterol levels. JAMA 1998;279:1615-1622.
52. Should you take drugs for cholesterol? The Johns Hopkins Medical Letter Health After 50 1998;10(8):1-2.
53. Hebert PR, Gaziano M, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. JAMA 1997;278:313-321.
54. The Fbst Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low density lipoprotein cholesterol levels and low dose anticoagulation on obstructive changes in saphenous-vein coronary artery bypass grafts. N Engl J Med 1997;336:153-162.
55. Radford MJ, Krumholz HM. Beta blockers after myocardial infarction-for few patients or many? N Engl J Med 1998;339:551-553.
56. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high risk and low risk patients after myocardial infarction. N Engl J Med 1998;339:489-497.
57. Getting tough with cholesterol. Harvard Heart Letter 1998;8(6):1-4.
58. Krumholz HM, Radford MJ, Wang Y, Chen J, Heiat A, Marciniak TA. JAMA 1998;280:623-629.
59. Office of Public Health and Science. Healthy people 2010 objectives: draft for public comment. Washington: US Department of Health and Human Services, 1998.
60. Waite LJ. The demographic face of America's elderly. Inquiry 1996;33:220-224.
61. Chrisp P, Lewis NJW, Milne RJ. Simvastatin a pharmacoeconoomic evaluation of its cost- effectiveness in hypercholesterolaemia and prevention of coronary heart disease. PharmacoEconomics 1992;1:124-145.
62. Hodgson TA. Costs of illness in cost-effectiveness analysis: a review of the methodology. PharmacoEconomics 1994;6:536-552.
63. Hodgson TA. Annual costs of illness versus lifetime costs of illness and implications of structural change. Drug Information J 1988;22:323-341.
64. Hodgson TA. Cigarette smoking and lifetime medical expenditures. Milbank Q 1992;70:81-125.
65. Hjalte K, Lindgren B, Persson U. Cost-effectiveness of simvastatin versus cholestyramine results for Sweden. PharmacoEconomics 1992;1:213-216.
66. Ford ES, Kelly AE, Teutsch SM, Thacker SB, Garbe PL. Radon and lung cancer: A cost-effectiveness analysis. Am J Public Health 1999;89:351-357.
67. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.